Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.

The invention relates to a process for the preparation of a rolled compressed collagen carrier and a process for un-rolling said rolled compressed collagen carrier. Said rolled compressed collagen carrier is ready for use in minimally invasive surgery. The invention also relates to a rolled compressed collagen carrier for use in the prevention or treatment of injury associated with performing minimally invasive surgery.

The invention relates to 55 newly discovered proteins, which are present in isolated purified protein complexes, derived medicinal products, recombinant DNA, engineered DNA, cDNA, monoclonal and natural products or synthesized products as part of nutrition, food, and/or supplemental products and their applications.

A method of alleviating central nervous system-mediated pain includes applying salmon thrombin at a neural injury site. Applying salmon thrombin can include applying a gel that includes salmon thrombin. The gel can also include fibrinogen, for example, salmon fibrinogen, human fibrinogen, or bovine fibrinogen. The salmon thrombin can be obtained from salmon plasma, or using recombinant technology, or by fractionation. A pain relief substance includes a gel that includes salmon thrombin.

The specification relates to a method of manufacturing a diabetic foot patient-specific skin regeneration sheet, and a diabetic foot patient-specific skin regeneration sheet.

Compositions and methods for therapeutic delivery are disclosed. More particularly, the present disclosure relates to nanoparticle compositions that sequester the activity of a target molecule while leaving other domains accessible to bind targeted tissues of interest. Methods for thrombus dissolution include administering a nanoparticle reversibly coupled to a target molecule that can dissolve a blood clot. Compositions and methods for inducing blood clotting are also disclosed. Methods for inducing blood clotting include administering a nanoparticle reversibly coupled to a target molecule that can induce the formation of a blood clot. Methods for sequestering a target molecule are also disclosed. The method includes reversibly coupling a target molecule to a nanoparticle having an affinity ligand that reversibly couples the target molecule, and thus, sequesters the target molecule activity until the target molecule interacts with its substrate resulting in the release of the target molecule.

Provided are pharmaceutical foam compositions comprising a peptone, a peptide hydrolysate or an enzymatically-hydrolyzed protein prepared by enzymatic hydrolysis of a full-length protein; methods of preparation and uses thereof.

The invention provides a new method of synthesizing cross-linked hyaluronic acids, compositions thereof, tubes and syringes containing such compositions alone or in combination with PRP/BMC, new devices for PRP/BMC preparation, and uses thereof in cell culture, skincare and joint preservation. The invention provides a method for the production of a crosslinked gel (preferably of desired molecular weight and/or concentration) from at least one first polymer (preferably hyaluronic acid), comprising the steps of: homogenizing said first polymer, hydrating said first polymer in a basic solution, crosslinking said basic solution by adding at the least one crosslinking agent at a higher temperature than room temperature, neutralizing said basic solution in an acidic solution, homogenizing said solution, mixing said solution with a supplemental quantity of a second polymer (preferably a second polymer of substantially the same molecular weight and/or concentration as said first polymer), and purifying said solution.

The present invention relates to a hemostatic composition including collagen, a stabilizer, and thrombin, and a container holding this hemostatic composition. The hemostatic composition and the container holding this hemostatic composition can be applied to an urgent bleeding patient by a simple method of use, and the hemostatic composition is less toxic, does not have a problem of blood infection, has a fast rate of biodegradation, has an excellent hemostatic effect, and can be usefully used as a hemostat.

The present invention relates to a hemostatic composition including collagen, a stabilizer, and thrombin, and a container holding this hemostatic composition. The hemostatic composition and the container holding this hemostatic composition can be applied to an urgent bleeding patient by a simple method of use, and the hemostatic composition is less toxic, does not have a problem of blood infection, has a fast rate of biodegradation, has an excellent hemostatic effect, and can be usefully used as a hemostat.